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CHORIONIC VILLUS SAMPLING AND THE RISK OF HYPERTENSIVE
DISORDERS OF PREGNANCY: A CASE CONTROL STUDY
Sanaz Ghazal, Mert O. Bahtiyar. Section of Maternal-Fetal Medicine, Department of
Obstetrics, Gynecology, and Reproductive Sciences, Yale University, School of
Medicine, New Haven, CT.
The purpose of this study was to determine whether there is an association between
chorionic villus sampling for prenatal diagnosis and the development of hypertensive
disorders of pregnancy. This study is a single-site retrospective case control study using
medical records of patients seen at Yale-New Haven Hospital. A total of 448 patients in
three groups (first trimester aneuploidy screening with nuchal translucency assessment,
genetic amniocentesis, and chorionic villus sampling) were included and data on maternal
characteristics, delivery outcomes, risk factors, and hypertensive outcomes were
recorded. Unadjusted odds ratios and odds ratios adjusted for maternal age and race were
calculated to compare the probability of gestational hypertension and preeclampsia
between the groups using the nuchal translucency group as the control.
In the genetic amniocentesis group, the adjusted odds ratio for gestational
hypertension was 1.9 (95% CI 0.2 – 170.1) and the ratio for preeclampsia was 1.4 (95%
CI 0.19-5.80), both statistically not significant. In the chorionic villus sampling group,
the adjusted odds ratio for gestational hypertension was 0.4 (95% CI 0.03 – 4.7) and the
ratio for preeclampsia was 0.93 (95% CI 0.8 – 1.07), again both statistically not
significant.
This study concluded that there is no association between chorionic villus sampling
and the development of hypertensive disorders of pregnancy.
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Introduction
Prenatal Diagnosis:
The advent of prenatal diagnostic techniques grew out of a desire on the part of
many mothers to be reassured that their unborn baby is healthy and without genetic
abnormalities. Various screening programs designed to provide reassurance of fetal
health differ in the amount of time needed to obtain results, rate of false positive results,
level of invasiveness, and safety for both mother and baby (1). Prenatal diagnosis of
structural, functional, or genetic abnormalities in the developing fetus provides valuable
information to both clinicians and patients during the pregnancy. This information may
lead to modifications in surveillance, the initiation of fetal therapy to optimize delivery,
or, in some cases, the consideration of pregnancy termination (2). It is important to select
a screening modality that will yield accurate results as early in the pregnancy as possible
in order to allow the option of pregnancy termination to be considered at a safe and more
discreet stage in the pregnancy.
Ultrasound can be used to detect anatomic malformation and maternal serum
screening can help detect an increased risk of trisomy and other fetal anomalies.
However, fetal cells are needed for the definitive diagnosis of chromosomal
abnormalities. These fetal cells can be obtained from the amniotic fluid surrounding the
fetus (amniocentesis) or from the placenta (chorionic villus sampling). These two modes
of invasive prenatal diagnosis will be discussed here.
On average, about 5-10% of pregnant women in the United States decide to
undergo invasive prenatal testing (3). Indications for invasive prenatal diagnostic testing
include maternal age greater than or equal to 35, family history of genetic disorders, prior
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history of a fetus with a chromosomal abnormality, a positive screening test, or a fetal
anomaly suspected on ultrasound.
The risks associated with invasive prenatal diagnostic techniques such as
amniocentesis and chorionic villus sampling have been widely studied. In light of the
increased risks associated with invasive procedures, many women opt for less invasive
ways to obtain genetic information about their fetus. This has led to a surge in the
number of women who are pursuing first trimester aneuploidy screening and nuchal
translucency assessment.

2
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First Trimester Aneuploidy Screening:
First Trimester Aneuploidy Screening (FTAS) was introduced in the 1990s as an
alternative to invasive diagnostic testing (4). First trimester screening protocols consist
of maternal serum analyte screening, ultrasound evaluation, or a combination of both in
addition to the assessment of maternal age (2). In the second trimester, maternal age can
be combined with levels of alpha-fetoprotein, human chorionic gonadotropin, and
unconjugated estriol to estimate the risk of fetal aneuploidy. This method identifies about
65 percent of fetuses with trisomy 21 with a 4.5 to 5.0 percent false positive rate. When
levels of inhibin A are added (quadruple screen), the detection rate increases to
approximately 75 percent (5).
Even though second trimester screening has been shown to be accurate and
effective, delaying screening until the second trimester can limit decision-making about
prenatal diagnosis and pregnancy termination. Chorionic villus sampling is an option for
prenatal diagnosis that is available to patients in the first trimester. Delayed screening
until the second trimester precludes the use of chorionic villus sampling for early
definitive genetic diagnosis and decisions about pregnancy termination must also be
delayed (5). Thus, an emphasis was placed on developing adequate first trimester
screening protocols that would provide pregnant women with more options for prenatal
diagnosis, including chorionic villus sampling in the first trimester, and would allow for
earlier and safer pregnancy termination.
In first trimester screening, the most useful maternal serum analytes are
pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human
chorionic gonadotropin (free beta-hCG) (6). Using maternal age in combination with
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levels of PAPP-A and free beta-hCG has resulted in Down syndrome detection rates of
60 to 65 percent (7)(8). Nuchal translucency (NT) assessment in the first trimester is
another method used to evaluate the risk of fetal aneuploidy. Nuchal translucency is
obtained by measuring the maximum thickness of the subcutaneous translucency between
the skin and the soft tissues behind the cervical spine in the midsagittal plane (9). This
hypoechoic region is thought to represent mesenchymal edema and, when enlarged, is
often associated with fetal aneuploidy (10). Ultrasound measurement of nuchal
translucency in combination with maternal age has been reported to independently detect
77 percent of Down syndrome cases with a false positive rate of 5 percent (11).
When the ultrasound measurement of nuchal translucency is combined with
biochemical evaluation of PAPP-A and free beta-hCG, the sensitivity of predicting risk
of fetal aneuploidy, particularly trisomy 21, is greatly enhanced. The combination of first
trimester ultrasound assessment and maternal serum screening was evaluated by two
large trials and was shown to be effective (2)(12)(13). In the First Trimester Maternal
Serum Biochemistry and Fetal Nuchal Translucency Screening Study (BUN study) by
Wapner et al., 8514 women underwent screening for trisomy 21 and trisomy 18 between
74 and 97 days of gestation using maternal age, maternal levels of free beta-hCG and
PAPP-A, and ultrasound measurement of nuchal translucency (12). Using a Down
syndrome risk cutoff of 1:270, this combined screening method detected 85.2 percent of
Down syndrome cases with a false positive rate of 9.4 percent. This study also reported
that screening identified 90.9 percent of trisomy 18 cases with a 2 percent false positive
rate.
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The First and Second Trimester Evaluation of Risk (FASTER) trial reported by
Malone et al. was another large multi-center trial that studied 33,546 women. Study
subjects underwent both first trimester screening, which included assessment of nuchal
translucency, levels of PAPP-A, and free beta-hCG as well as second trimester quadruple
screening, which included measuring levels of maternal alpha-fetoprotein, total hCG,
unconjugated estriol, and inhibin A (13). If either the first or second trimester screening
test was positive, the patient was offered fetal karyotyping. The authors compared the
detection rates of first trimester screening, second trimester screening, and combined first
and second trimester screening (fully integrated screening). Using a Down syndrome risk
cutoff value of 1:270 and a 5 percent false positive rate, the authors reported Down
syndrome detection rates for first trimester screening of 87 percent, 85 percent, and 82
percent for testing done at 11, 12, and 13 weeks, respectively. The second trimester
quadruple screen detection rate for Down’s syndrome was 81 percent. The fully
integrated screening (single risk result provided) yielded the best results and detected 96
percent of Down syndrome cases.
First trimester aneuploidy screening does have a few drawbacks. There is a
relatively narrow window of time to perform the screening, usually between 11 and 14
weeks gestation depending on crown-rump length. Additionally, the accurate assessment
of gestational age is an essential element of calculating risk. It was also noted by the
authors of the FASTER trial that nuchal translucency measurements performed as part of
the screening protocol can be difficult to perform accurately (13). Nuchal translucency
measurements can vary from operator to operator based on experience and technique and
they can also vary by a single operator over time. Other factors that can complicate
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accurate measurements include suboptimal fetal position and poor visibility (2). Despite
these drawbacks, the data shows that first trimester aneuploidy screening is a safe and
accurate testing modality that can be used as an alternative to invasive prenatal diagnosis
or as a tool to help clinicians determine which patients should be offered definitive
genetic testing.
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Genetic Amniocentesis:
Amniocentesis is a technique in which amniotic fluid is aspirated from the uterine
cavity for both diagnostic and therapeutic purposes. One of the main diagnostic
indications for the procedure is prenatal genetic testing and fetal karyotyping. In 1956,
Fuchs and Riis were the first to report on the use of amniocentesis for genetic diagnosis
when they discovered that cells from amniotic fluid could be used to determine fetal sex
(14). Over 50 years later, amniocentesis has become a standard tool used by obstetricians
and gynecologists for the diagnosis of fetal malformations and genetic abnormalities.
Other diagnostic indications include the assessment of fetal lung maturity and evaluation
of the fetus for infection, degree of hemolytic anemia, hemoglobinopathy, neural tube
defects, and coagulopathy. The most common therapeutic indication of amniocentesis is
the removal of excess amniotic fluid.
Amniocentesis is usually performed between 14 and 20 weeks gestation, typically
around 16 weeks. The procedure is done during this time because there is believed to be
enough amniotic fluid surrounding the fetus to extract an adequate amount for sample
without significant technical difficulties (1). Early amniocentesis, which is typically
performed between 11 and 14 weeks gestation, has been widely studied in comparison to
second trimester amniocentesis. The technique for early amniocentesis is the same as
midtrimester amniocentesis, however, early amniocentesis requires greater technical skill
by the operator and a smaller volume of fluid is removed (2). The accuracy of the
cytogenetic findings between early amniocentesis and second trimester amniocentesis is
similar (> 99%), however there is a higher rate of culture failure with early versus
midtrimester amniocentesis (15)(16). Furthermore, studies have shown an increased risk
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of fetal loss with early amniocentesis compared to midtrimester amniocentesis. In the
Canadian Early and Mid-trimester Amniocentesis Trial (CEMAT), researchers studied
4374 women randomized to undergo early amniocentesis before 13 weeks gestation or
midtrimester amniocentesis after 15 weeks gestation and found a significant difference in
the rate of fetal loss in the early amniocentesis group compared to the midtrimester
amniocentesis group (7.6% vs. 5.9%, p = 0.012). They also noted a higher incidence of
talipes equinovarus, a congenital deformity of the foot, in the early amniocentesis group
than in the midtrimester amniocentesis group (1.3% vs. 0.1%, p = 0.0001)(10). Because
midtrimester amniocentesis is considered safer and less technically demanding, many
centers no longer perform early amniocentesis. Performing genetic amniocentesis
beyond 20 weeks is possible, but can be problematic if pregnancy termination is a
consideration in the setting of abnormal findings.
Amniocentesis is typically done in an outpatient or ambulatory setting. The
procedure begins with the patient in the supine position and a sterile preparation. An
ultrasound assessment is performed first to confirm fetal viability, fetal position, and
placental location. An anatomic survey and biometry are also usually performed at this
time. Using continuous ultrasound guidance to avoid the placenta, umbilical cord, fetus,
and maternal bowel and bladder, a 20- to 22-gauge spinal needle is inserted through the
maternal abdominal wall and into the amniotic sac. Approximately 20 to 30 milliliters of
amniotic fluid is collected and sent for cell culture and fetal karyotyping. The needle is
then removed, the puncture site is observed for bleeding, and the fetal heart rate is
assessed and documented. Side effects immediately after the procedure are rare and
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generally mild, however, patients may experience uterine cramping, transient vaginal
spotting, and amniotic fluid leakage after the procedure (2).
Potential complications of genetic amniocentesis that should be discussed with
patients prior to the procedure include direct fetal injury, indirect fetal injury, leakage of
fluid, infection, and pregnancy loss. The risk of direct fetal injury with the needle is rare,
particularly since the vast majority of procedures are now performed with continuous
ultrasound guidance and visualization of the needle tip throughout the procedure. In a
randomized study of ultrasound-guided amniocentesis by Tabor et al. there was no
evidence of direct fetal injury in 2239 pregnancies (17). There have been isolated case
reports of fetal injuries such as skin dimples, ocular injury, and intracranial and bowel
abnormalities that have been associated with amniocentesis, however, there is no direct
evidence to support these associations (18)(19). A few studies have reported an increased
prevalence of indirect fetal injury secondary to amniocentesis, such as orthopedic
malformations and respiratory complications, however, the data has been inconsistent
(17). Several case reports have described mother to infant transmission of infection by
amniocentesis, particularly in women who are infected chronically (20). The Pediatric
AIDS Clinical Trials Group reported an increased rate of vertical transmission to infants
in HIV-infected women who underwent amniocentesis compared to HIV-infected women
who did not undergo amniocentesis (36% vs. 14%). However, they also showed that the
rate of vertical transmission of HIV is reduced in treated versus untreated women (21).
Perhaps the most widely studied complication of amniocentesis is the risk of fetal
loss. In 2006, the First And Second Trimester Evaluation of Risk for Aneuploidy Trial
(FASTER trial) studied the procedure-related pregnancy loss rate after second trimester
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amniocentesis (22). A total of 35,003 unselected patients were enrolled in the study,
where 3,096 patients underwent midtrimester amniocentesis and 31,907 did not and were
considered the control group. This study showed that the spontaneous fetal loss rate prior
to 24 weeks gestation in the amniocentesis group was not statistically significant from the
background loss rate in the control group (1.0% vs. 0.94%, p = 0.74). They also
determined that the procedure-related loss rate after amniocentesis was 0.06 percent (1.0
percent minus the 0.94 percent background loss rate in controls) and concluded that there
was no significant difference in fetal loss rate between women undergoing amniocentesis
and those who did not. There were several pitfalls with this study, such as the low
background loss rate for the control group, which called into question the applicability of
the results. To date, the randomized study performed by Tabor et al. in 1986 provides the
best estimate of the risk of fetal loss after amniocentesis (1)(17). In a low risk population
with a background pregnancy loss rate of 2 percent, midtrimester amniocentesis increases
the risk of pregnancy loss by another 1 percent.
The main advantage of midtrimester amniocentesis is that it can provide accurate
information regarding genetic or chromosomal abnormalities in a fetus and in the hands
of a skilled operator the procedure is safe. The results of the test are generally available
in two to three weeks. This long waiting period for results is one of the major
disadvantages of midtrimester amniocentesis, particularly when pregnancy termination is
desired based on abnormal test results. The need for genetic information earlier in the
pregnancy prompted clinicians to explore other forms of prenatal diagnostic testing, such
as chorionic villus sampling.
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Chorionic Villus Sampling:
Chorionic villus sampling (CVS) is a procedure used for the prenatal diagnosis of
genetic abnormalities, which involves sampling the placenta for chromosome or DNA
analysis. CVS was first introduced in the late 1960s when Scandinavian researcher Jan
Mohr performed a transcervical biopsy of the chorion. Chorionic villi are the precursor
of the placenta and can be used for genetic testing of the fetus. The adoption of chorionic
villus sampling into standard practice wavered in light of studies showing the relative
safety and accuracy of amniocentesis compared to CVS. However, with advancements in
ultrasound technology and molecular genetics, the desire for earlier prenatal diagnosis
increased and the demand for chorionic villus sampling slowly increased.
CVS is typically performed in the first trimester after 10 weeks gestation
compared to second trimester amniocentesis, which is generally performed between 15
and 17 weeks gestation. Thus, CVS provides mothers with genetic information earlier in
the pregnancy, which is imperative to many mothers who would consider pregnancy
termination in the setting of abnormal results. Performing CVS prior to 10 weeks
gestation has been shown to be associated with an increased frequency of oromandibular
defects and limb-reduction defects, with the incidence of defects reported to be as high as
1 to 2 percent (23)(24). Researchers have found that the incidence of limb-reduction
defects is about 6 per 10,000 when CVS is performed after 9 weeks, which is the same as
the background incidence (25). Thus, clinicians recommend waiting until after 10 weeks
to undergo the procedure.
CVS is generally performed as an ambulatory or outpatient procedure. An
ultrasound is performed before the procedure to document fetal viability, confirm the
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number of embryos, detect any fetal structural abnormalities, and to locate the placenta.
The procedure may be performed using either a transabdominal or transcervical
approach. The transabdominal approach begins with placing the woman in the supine
position, locating the placenta with a transabdominal ultrasound, and prepping the lower
abdomen in a sterile fashion. Under continuous ultrasound guidance, a 20-gauge needle
is inserted transabdominally and advanced until it penetrates the long axis of the placenta.
A syringe containing medium for the tissue sample is mounted and attached to the needle
hub. The needle tip is oscillated back and forth within the placenta in order to aspirate an
adequate sample of tissue. After the needle is removed, ultrasound is used to document
fetal movement. The tissue sample in medium is then sent for cell culture and fetal
karyotyping.
If a transcervical approach is planned, cervicovaginal cultures should be obtained
to identify any potential infection that may require antibiotic therapy prior to the
procedure. For this approach, the woman is placed in the lithotomy position and the
external and internal genitalia are prepped in a sterile fashion. A speculum is inserted
into the vagina and ring forceps are used to grasp the cervix and gently pull it towards the
operator in order to manipulate the uterus into a more axial position. Under continuous
ultrasound guidance, a metal sound is inserted into the endocervical canal to determine its
curvature. A transcervical cannula is then bent to resemble the same curvature and, under
ultrasound guidance, is inserted through the endocervical canal until the placenta is
reached. A syringe containing medium is attached to the catheter. The needle is then
moved back and forth within the placenta in order to obtain an adequate sample of tissue.
The aspirated tissue in medium is then sent for cell culture and fetal karyotyping.

CVS and Hypertensive Disorders of Pregnancy

13

The choice of whether to perform the procedure transvaginally or transcervically
is dependent in part on the location of the placenta and in part on the operator’s personal
preference and skill (26). If the placenta is in an anterior position, a transabdominal
approach may be safer, whereas a transcervical approach may allow easier access to a
placenta that is in a posterior position. A learning curve has been described for
successful and safe performance of the procedure (27). The operator should be adept
with the use of ultrasound in order to visualize the needle tip and the relevant anatomy or
have an experienced sonographer assist with the procedure.
The indications for CVS are in essence the same as those for amniocentesis. The
most common indication is an increased risk of fetal aneuploidies due to advanced
maternal age, family history of genetic disorders, or an abnormal first trimester screening.
Contraindications to transcervical CVS include vaginismus, cervical stenosis, cervical or
lower uterine segment myomas, active genital tract infection, severe anteflexion or
retroflexion of the uterus such that uterine assess impaired, and body habitus that
precludes clear ultrasound visualization or uterine assess (2). Contraindications to
transabdominal CVS include extreme uterine retroflexion with obstructive intestinal
loops or fetal position that obstructs access to a posterior placenta. Relative
contraindications to both modes include vaginal bleeding or spotting, maternal
isoimmunization, presence of an intrauterine device (IUD), and the presence of risk
factors for neural tube defects (2). Unsensitized Rh negative women should be given
anti-D immunoglobulin prophylaxis after undergoing the procedure. Chorionic villus
tissue samples cannot be used for alpha-fetoprotein (AFP) testing for neural tube defects.
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There are several advantages to pursuing chorionic villus sampling over
midtrimester amniocentesis. The main advantage is that CVS can be safely performed in
the first trimester, as early as 10 weeks gestation, whereas amniocentesis is generally not
performed before 14 weeks gestation. This advantage may be especially important for a
mother who would consider pregnancy termination in the face of abnormal results.
Furthermore, the results of CVS are available more quickly than with midtrimester
amniocentesis. CVS allows for a larger amount of DNA to be extracted, which allows
for more reliable DNA analysis within days of sampling. There is also some data to
suggest that there is a smaller risk of culture failure with CVS compared to midtrimester
amniocentesis (1).
Despite these advantages, there are several disadvantages and complications
that must be weighed against the benefit of earlier testing and results. First, safe and
successful CVS requires a higher level of skill, expertise, and experience than
amniocentesis. There is also a higher incidence of mosaic results with CVS compared to
amniocentesis (1). Chromosomal mosaicism is the presence of two or more cell lines
with different karyotypes in a single sample.
Perhaps the most important complication to consider is the increased risk of fetal
loss with CVS compared to midtrimester amniocentesis. A Cochrane review in 2003
compared the safety and efficacy of transcervical CVS, transabdominal CVS, and
midtrimester amniocentesis, which was defined as amniocentesis after 15 weeks gestation
(1). The review included 14 randomized studies that analyzed pregnant women
undergoing invasive prenatal diagnostic testing for fetal genetic abnormalities. Four
trials that compared transcervical CVS to midtrimester amniocentesis were analyzed
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(28)(29)(30)(31). They found a higher total pregnancy loss rate that was consistently
higher in the patients who underwent transcervical CVS (14.5% vs. 11%) and this overall
difference was statistically significant except in the Canadian trial by Lippman et al. in
1992 (28). When transabdominal CVS was compared to midtrimester amniocentesis,
they found no significant difference in total pregnancy loss (6.3% vs. 7%) (29).
Two trials in the Cochrane review presented data comparing CVS by any route
and midtrimester amniocentesis (29)(32). This data showed that the overall pregnancy
loss rate was higher after CVS than midtrimester amniocentesis (11% vs. 8.2%) and that
this difference was statistically significant (RR 1.43, 95% CI 1.22-1.67). They also found
that more repeat tests were necessary after transcervical CVS than midtrimester
amniocentesis (6.3% vs. 0.2%), there were more problems analyzing placental tissue
from CVS than analyzing amniotic fluid from amniocentesis. When transcervical CVS
was compared to midtrimester amniocentesis, the transcervical CVS group had a higher
rate of laboratory failure (1.7% of cases vs. 0.07%), more cytogenetic abnormalities
confined only to placenta (2.3% vs. 0.4%), and more false positive and false negative
results (2.2% vs. 0.2% and 0.3% vs. 0%, respectively) than the midtrimester
amniocentesis group (1). It was noted that complications after either procedure were
uncommon and none were life-threatening. Vaginal bleeding was more common after
transcervical CVS and there was no significant difference in amniotic fluid leakage postprocedure (1)(32).
When transcervical and transabdominal CVS were compared head-to-head, the
Cochrane review reported that transabdominal CVS is associated with a significant
reduction in both total pregnancy loss (RR 1.23, 95% 1.06-1.42) and spontaneous
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miscarriage (RR 1.75, 95% CI 1.33-2.29). The success of cytogenetic analysis was
comparable for both procedures, but transcervical CVS appeared to be more technically
demanding, required multiple insertions more frequently (11.2% vs. 4.1%), and caused
more vaginal bleeding (10% vs. 1.6%).
The overall conclusions drawn by the Cochrane review were that midtrimester
amniocentesis is safer than transcervical CVS or early amniocentesis performed before
15 weeks gestation. The authors reiterated that the benefits of early prenatal genetic
diagnosis must be weighed carefully against the increased risks of performing more
technically demanding and invasive procedures. If early diagnosis is required or desired,
transabdominal CVS is the preferred method to early amniocentesis or transcervical CVS.
If transabdominal CVS is technically difficult or not possible, transcervical CVS in the
first trimester or midtrimester amniocentesis should be considered (1).
A more recent review compiled data from over 45 articles on the procedurerelated complications of amniocentesis and chorionic villus sampling (33). This review
reported that the pooled pregnancy loss within 14 days of midtrimester amniocentesis
was 0.6 percent (95% CI 0.5-0.7), pregnancy loss before 24 weeks was 0.9 percent (95%
CI 0.6-1.3), and total pregnancy loss was 1.9 percent (95% CI 1.4-2.5). This was
compared to CVS which had corresponding figures of 0.75 percent, 1.3 percent, and 2.0
percent (95% CI 1.4-2.6). This study highlighted some of the major limitations hindering
many of the studies looking at risk related to prenatal diagnostic testing. The background
risk of women who undergo CVS is generally higher than those who undergo
amniocentesis because amniocentesis is performed later in the pregnancy at a gestational
age when the risk of spontaneous miscarriage is lower. Many of the studies used in these

CVS and Hypertensive Disorders of Pregnancy

17

reviews were nonrandomized and lacked adequate control groups, which makes it
difficult to estimate the true risk of the procedures.
Chorionic villus sampling provides an alternative to early amniocentesis for
women who desire prenatal genetic information in the first trimester. CVS has been
proven safe and effective in the hands of an experienced and skilled operator, however
there are several risks that should be discussed with the patient and weighed against the
benefit of earlier genetic diagnosis. Given the risks associated with chorionic villus
sampling, many women often opt for less invasive ways of obtaining information about
the genetic composition and general well-being of their baby, such as first trimester
aneuploidy screening with nuchal translucency.
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Hypertensive Disorders of Pregnancy:
There are several major hypertensive disorders that can complicate pregnancy and
collectively they form a major cause of maternal morbidity and mortality. Preeclampsia
(PEC) is defined as new onset hypertension after 20 weeks gestation in a previously
normotensive woman and the presence of new onset proteinuria. Based on the degree of
hypertension, the degree of proteinuria, and on presence of symptoms, preeclampsia can
be classified as mild or severe. Table 1 shows the definitions of hypertensive disorders
that occur in pregnancy, including the distinction between mild and severe preeclampsia.
Eclampsia (EC) is defined as the presence of seizures not attributable to any other cause
in a woman with preeclampsia. Chronic hypertension (or preexisting hypertension) is
defined as a systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg,
or both that is present before 20 weeks gestation or persists beyond 12 weeks postpartum.
Chronic hypertension (CHTN) can be a primary disorder or it can be secondary to other
medical disorders. Gestational hypertension (previously called pregnancy-induced
hypertension or PIH) refers to hypertension without proteinuria or other signs of
preeclampsia that develops after 20 weeks gestation in a previously normotensive
woman. Gestational hypertension (GHTN) should resolve by 12 weeks postpartum. If
the hypertension persists after 12 weeks postpartum, then the diagnosis is likely chronic
hypertension that was masked in the early stages of pregnancy. About 25 percent of
women diagnosed with gestational hypertension will go on develop preeclampsia later in
the pregnancy (34).
The exact incidence of preeclampsia is unknown and reports vary depending on
the study population (2)(35). It has been reported that hypertensive disease complicates
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between 12 to 22 percent of pregnancies and is responsible for 17.6 percent of maternal
deaths in the United States (35)(36). Chronic hypertension occurs in about 3 percent of
pregnancies and gestational hypertension develops in about 6 percent of pregnancies (37).
It has been reported that preeclampsia occurs in 3 to 14 percent of all pregnancies
worldwide and in about 5 to 8 percent of pregnancies in the United States (2). One study
reported that in the United States, 75 percent of preeclampsia cases are classified as mild
and 25 percent of cases are severe (38). Preeclampsia is considered one of the leading
causes of maternal death, along with hemorrhage, embolism, and infection, and the
condition also contributes to the rate of stillbirths and neonatal morbidity and mortality
(2)(39).
Several risk factors for the development of preeclampsia have been identified (40).
Women with a previous history of preeclampsia are at a serious increased risk of
developing preeclampsia (RR 7.19, 95% CI 5.85-8.83) compared to women with no
history of preeclampsia. Advanced maternal age or maternal age greater than or equal to
40 is an independent risk factor for preeclampsia with a relative risk of 1.96 for
multiparous women (95% CI 1.34-2.87). Nulliparity increases the risk for developing
preeclampsia (RR 2.91, 95% CI 1.28-6.61), although the reason for this association is
unclear. Patients with pre-existing diabetes are also at increased risk (RR 3.56, 95% CI
2.54-4.99) compared to women with no history of diabetes. Multiple gestation is another
risk factor with the relative risk for twin pregnancies being 2.93 (95% CI 2.04-4.21) and
this risk increases as the number of fetuses increases. Obesity as determined by body
mass index (BMI) has been shown to increase the risk of developing preeclampsia. In
one study, the relative risk of preeclampsia in a woman with an increased pre-pregnancy
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BMI is 2.47 (95% CI 1.66-3.67) and the relative risk in a woman with an increased BMI
on admission (pregnancy BMI) is 1.55 (95% CI 1.28-1.88). There is also an increased
prevalence of hypertensive disorders in African-American patients compared to
Caucasian patients. Other risk factors include preexisting hypertension, antiphospholipid
syndrome, prolonged interval between pregnancies, vascular and connective tissue
disease, and a family history of preeclampsia (2)(35)(40).
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CVS and Hypertensive Outcomes: Background Literature
A thorough understanding of the pathophysiology of preeclampsia remains
elusive and several theories for the development of preeclampsia have been proposed.
One theory in the literature suggests that preeclampsia may be related to abnormal
placentation in the early stages of pregnancy. Given this theory, Silver et al. asked
whether the placental disruption caused by invasive prenatal diagnostic procedures early
in the pregnancy is correlated with the development of hypertensive disorders later in
pregnancy (41). This study obtained subjects from a randomized trial by the National
Institute of Child Health and Human Development, which compared early amniocentesis
and transabdominal chorionic villus sampling in weeks 13 and 14. They compared the
rate of hypertensive outcomes in patients with different degrees of placental disruption.
A total of 3,698 randomized patients with genetically normal pregnancies were studied
and 3 cohorts were compared: late CVS in which the placenta was directly sampled, early
amniocentesis in which the placenta was traversed, and early amniocentesis in which the
placenta was not traversed. They proposed that placental disruption is greatest for the
CVS group because a sample of the chorionic villus is removed and least for the early
amniocentesis group in which the placenta was not traversed.
A diagnosis of gestational hypertension or preeclampsia was made in 166 patients
(4.5%). Their results showed a significantly higher rate of gestational hypertension or
preeclampsia in women undergoing CVS compared to women undergoing early
amniocentesis (5.4% vs. 3.5%, p = 0.005). A stepwise difference in risk of hypertensive
outcome was found with the highest risk being the CVS group (5.4%), the next highest
risk being the early amniocentesis group in which the placenta was traversed (3.9%), and
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the lowest risk being the early amniocentesis group in which the placenta was not
traversed (3.4%, p = 0.02). According to this data, the likelihood of gestational
hypertension or preeclampsia is greater as the degree of placental disruption increases.
The authors concluded by saying that this data supports the theory that disturbances in
early placentation lead to maternal hypertension later in pregnancy. Several limitations
of the study were discussed by the authors including the possibility that misclassification
could have occurred given that the subjects of the study were obtained through another
trial that was not designed to study hypertensive outcomes as a primary endpoint.
In a more recent study, Adusumalli et al. conducted a retrospective review to
analyze the possible relationship between chorionic villus sampling between 10 and 13
weeks and hypertensive disorders of pregnancy (42). This study enrolled 1540 women
who underwent CVS between 10 and 13 weeks gestation and 840 control subjects who
underwent first-trimester screening with nuchal translucency assessment and biochemical
testing between 11 and 13 weeks gestation. A total of 76 (4.9%) of patients in the
chorionic villus sampling group were diagnosed with hypertensive disorders of
pregnancy compared to 37 (4.4%) patients in the control group (p = 0.31). They
concluded that there was no association between CVS at 10 to 13 weeks and hypertensive
disorders of pregnancy. However, they did find an association between CVS and severe
hypertensive disorders which included severe preeclampsia, eclampsia, and HELLP
(Hemolysis, Elevated Liver enzymes, and Low Platelet count) syndrome.
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Purpose
The purpose of this study was to compare patients who underwent chorionic villus
sampling with patients who underwent first trimester aneuploidy screening with nuchal
translucency assessment to determine whether there is an association between chorionic
villus sampling and the development of hypertensive disorders later in the pregnancy.
This study was initiated in the context of recent studies that presented conflicting data
regarding the association between chorionic villus sampling and hypertensive outcomes
in pregnancy. We hypothesized that there is no association between chorionic villus
sampling and the development of hypertensive disorders in pregnancy.
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Methods
This study is a single-site retrospective case control study using medical records
of patients seen at Yale-New Haven Hospital. Approval was obtained by our institution’s
Human Investigations Committee on August 1, 2007. Study subjects were identified
through records maintained by the Department of Obstetrics, Gynecology, and
Reproductive Sciences at Yale-New Haven Hospital of patients who had undergone
chorionic villus sampling, genetic amniocentesis, and first trimester aneuploidy screening
with nuchal translucency assessment at our institution. Patient data was collected from
both inpatient and outpatient medical records.
Only singleton gestations were investigated because multiple gestational
pregnancies are already at higher risk of hypertensive complications of pregnancy. We
evaluated patients who underwent genetic amniocentesis or CVS between January 1,
2000 and December 31, 2006. Our control group was composed of patients who
underwent first trimester aneuploidy screening during the same time period without any
invasive testing. Patients who underwent first trimester aneuploidy screening with nuchal
translucency measurement as well as invasive prenatal diagnosis (genetic amniocentesis
or CVS) were excluded from the control group. This study included only patients who
delivered at Yale-New Haven Hospital during this time period.
Data regarding the mode of CVS, evidence of fetal anomalies, gestational age at
the time of procedure, and gestational age and birth weight at the time of delivery was
recorded. We also documented the presence of known risk factors for hypertensive
outcomes, including maternal age, BMI, race, gravidity and parity, order, presence and
extent of maternal diabetes, smoking history, and previous history of preeclampsia or
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other hypertensive disorders. The presence of maternal diabetes was documented
according to the White classification of diabetes and pregnancy (43).
We utilized definitions for hypertensive disorders of pregnancy outlined by the
American College of Obstetrics and Gynecology guidelines and the report of the National
High Blood Pressure Education Program Working Group (35)(44). Chronic hypertension
was defined as hypertension that was present before 20 weeks gestation. Gestational
hypertension was defined as hypertension detected for the first time after 20 weeks
gestation without proteinuria. Mild preeclampsia was defined using the following
criteria: (1) blood pressure greater than 140/90 that occurs after 20 weeks gestation in a
previously normotensive woman and (2) proteinuria of at least 300 milligrams in a 24hour specimen or 1+ on urine dipstick (44). Severe preeclampsia was defined using the
following criteria: (1) blood pressure greater than 160/110 measured on 2 occasions at
least 6 hours apart, (2) proteinuria of at least 5 grams in a 24-hour collection or 3+ or
greater on urine dipstick, (3) oliguria of less than 500 milliliters in 24 hours, (4)
thrombocytopenia, (5) elevated hepatic enzymes or impaired liver function, (6) persistent
headache, visual disturbances, or other cerebral disturbances, (7) persistent epigastric
pain or right upper-quadrant pain, and (8) fetal growth restriction (29). Eclampsia was
defined as the presence of preeclampsia and seizures that are not attributable to any other
cause (29).
The prevalence of hypertensive disorders was compared among the three groups.
Unadjusted odds ratios were calculated and compared. Odds ratios were then adjusted
for maternal age and race. Unadjusted odds ratios were also calculated to assess any
association between race and the development of gestational hypertension and
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preeclampsia as well as the association between smoking history and the development of
hypertensive disorders. Statistical analyses were performed using SPSS 14.0 (SPSS, Inc.
Chicago, IL).
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Results
Data from 124 women who underwent first trimester aneuploidy screening with
nuchal translucency assessment (NT group), 119 women who underwent genetic
amniocentesis (GA group), and 205 women who underwent chorionic villus sampling
(CVS group) at Yale-New Haven Hospital between January 2000 to December 2006 was
gathered and analyzed. The number of patients was limited by the fact that only patients
who delivered at Yale-New Haven Hospital were included in the study. The NT group
was used as the control group for this study. Table 2 summarizes information obtained
from medical records at our institution on maternal characteristic, risk factors, and
delivery outcomes. The mean maternal age for the NT group, GA group, and CVS group
were 32.9, 36.9, and 36.2, respectively. The majority of patients in all three groups were
Caucasian. There were more African-American patients in the NT group than in either
the GA group or CVS group and there were more Asian women and fewer Hispanic
women in the GA group compared to the other two groups. The presence of maternal
diabetes of any class among the three groups was 8.9 percent, 7.6 percent, and 6.3
percent, respectively. The majority of all women in the study were nonsmokers, however
there were slightly more smokers and ex-smokers in the NT group than the in GA or CVS
group.
The prevalence of hypertensive disorders by group is shown in Table 3. Chronic
hypertension was present in 3.2 percent, 4.2 percent, and 3.4 percent of the NT, GA, and
CVS groups, respectively. There were slightly more patients with gestational
hypertension in the NT group compared to the GA and CVS groups. Three patients
(1.5%) in the CVS group had mild preeclampsia compared to one patient in the NT group
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and no patients in the GA group. The prevalence of severe preeclampsia was similar in
all three groups. The total prevalence of preeclampsia, both mild and severe, across all
three groups was 2.7 percent.
Odds ratios were calculated to compare the probability of gestational hypertension
and preeclampsia between the groups using the NT group as the control. Table 4 shows
the unadjusted odds ratios for gestational hypertension and preeclampsia in the GA and
CVS groups compared to the NT group. In the genetic amniocentesis group, the
unadjusted odds ratio for gestational hypertension was 3.5 (95% CI 0.6-19.3). When the
odds ratio was adjusted for maternal age and race, the odds ratio decreased to 1.9 (95%
CI 0.2-170.1). The same trend was seen in the CVS group. The unadjusted odds ratio for
gestational hypertension in the CVS group was 0.9 (95% CI 0.1-9.6) and when adjusted
for maternal age and race, the odds ratio becomes 0.4 (95% CI 0.03-4.7). However, none
of these findings are significant. When unadjusted odds ratios for preeclampsia in the
GA and CVS groups were examined, they were identical (0.8). When adjusted for
maternal age and race, the odds ratio in the GA group became 1.04 (95% CI 0.19-5.80)
and the odds ratio in the CVS group became 0.93 (95% CI 0.8-1.07). These values were
also not significant.
Table 5 shows the unadjusted odds ratio for both gestational hypertension and
preeclampsia based on race. For gestational hypertension, all races except AfricanAmerican had an odds ratio of 1.0. The unadjusted odds ratio for African-American
ethnicity and gestational hypertension was 18.8 (95% CI 3.5-102.6) and this value was
significant (p < 0.05). For preeclampsia, the only significant unadjusted odds ratio was
for Hispanic race (odds ratio = 7.8, 95% CI 1.4-42.8, p < 0.05).
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Smoking status was also evaluated for a possible association with gestational
hypertension and preeclampsia (Table 6). The unadjusted odds ratio for patients who
smoked during the pregnancy and gestational hypertension was 8.2 (95% CI 0.9-76.4)
and that of ex-smokers who did not smoke during the pregnancy was 7.4 (95% CI 0.868.9). These values were also not statistically significant.
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Discussion
Summary of Results:
A total of 448 patients were evaluated in this study to assess the relationship
between chorionic villus sampling and the development of hypertensive outcomes in
pregnancy. Three groups were compared: patients who underwent first trimester
aneuploidy screening with nuchal translucency measurement (control group), patients
who underwent genetic amniocentesis, and patients who underwent chorionic villus
sampling. Odds ratios, both unadjusted and adjusted for maternal age and race, and 95%
confidence intervals were calculated.
This study found no association between chorionic villus sampling and gestational
hypertension or preeclampsia. Unadjusted and adjusted odds ratios for genetic
amniocentesis and chorionic villus sampling and the development of gestational
hypertension or preeclampsia were not significant, which was consistent with our
expectations. The data also highlights an association between African-American race and
gestational hypertension (unadjusted odds ratio = 18.8, 95% CI 3.5-102.6, p < 0.05),
which was significant and also expected. An association between Hispanic race and the
development of preeclampsia (unadjusted odds ratio = 7.8, 95% CI 1.4-42.8, p < 0.05)
was both noted and significant. Data on the association between smoking status and
gestational hypertension or preeclampsia was also evaluated. Patients who smoked
during the pregnancy or who were ex-smokers had higher unadjusted odds ratios for
gestational hypertension (unadjusted odds ratio = 8.2 and 7.4, respectively) when
compared to nonsmokers. This data approached statistical significance though it did
ultimately reach significance (smoker 95% CI 0.9-76.4, ex-smoker 95% CI 0.8-68.9).
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Limitations and Future Directions:
There were several limitations in this study. The number of patients in the nuchal
translucency group and genetic amniocentesis group was substantially less than the
chorionic villus sampling group and the overall sample size of the study was relatively
small. This was due, in part, to the difficulty in obtaining complete demographic and
obstetrical outcome data for women who were eligible for inclusion into the study. In
addition, the number of patients included in the study at the outset was limited to only
those who delivered at Yale-New Haven Hospital. Given the relatively small sample
size, the power of this study was significantly low making it difficult to draw definitive
conclusions based on the data.
Additionally, the number of patients diagnosed with preeclampsia in all three
groups was lower than the estimated incidence of preeclampsia in the United States,
which is about 5 to 8 percent of all pregnancies (2). It is unclear why there was a lower
incidence of preeclampsia in our study population. It could have been due to selection or
sampling bias during the data collection phase of this study. We limited our study
population to only those patients that delivered at Yale-New Haven Hospital. It is also
possible that some patients may have been misclassified or they may have had
incomplete data points. This bias makes our data difficult to apply because it suggests
that perhaps our study population may not be entirely representative of the population at
large.
This study would have been made stronger with a larger sample size and
relatively equal numbers in each of the three patient groups. The success of a study of
this nature is largely dependent on the presence of adequate controls and complete
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demographic and risk factor data to control for possible confounders. Having more
complete data would have allowed for more patients to be included in the study and
would have provided more variables to adjust in our final calculations. We initially
obtained data on body mass index (BMI) both pre-pregnancy and during the pregnancy,
however, we did not have enough data on enough patients to adequately analyze the
relationship between BMI and hypertensive outcomes. Other parameters that may be of
study interest in the future include villus sample size, number of device insertions, and
the use of assisted reproductive technology.

CVS and Hypertensive Disorders of Pregnancy

33

Conclusion:
In conclusion, the results of this study support previous data that has shown no
association between chorionic villus sampling and the development of hypertensive
disorders later in pregnancy. Though our study is limited by a small sample size and low
statistical power, we did not find any statistically significant increase in the odds ratio
between patients undergoing genetic amniocentesis or chorionic villus sampling and the
development of either gestational hypertension or preeclampsia. Even when the odds
ratios were adjusted for maternal age and race, there was still no statistical difference
among the three patient groups. An association was noted between African-American
race and gestational hypertension, which has been supported by previous studies. Given
the low power of our study, we suggest that a larger retrospective case control study be
conducted in order to more accurately determine the relationship between chorionic villus
sampling and hypertensive outcomes in pregnancy.
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Figures and Tables
Table 1. Definitions of Hypertensive Disorders of Pregnancy
Chronic Hypertension
• BP ≥ 140/90 mmHg on two occasions that presents before 20 weeks gestation
Gestational Hypertension
•

BP ≥ 140/90 mmHg on two occasions in a previously normotensive woman

•

No proteinuria

• BP returns to normal < 12 weeks postpartum
Preelampsia
Mild:
• BP ≥ 140/90 mmHg on two occasions after 20 weeks gestation
•

Proteinuria ≥ 300mg/24 hours or ≥ 1+ dipstick

Severe:
• BP ≥ 160/110 mmHg on two occasions at least 6 hours apart
•

Proteinuria 5.0g/24 hours or ≥ 3+ dipstick

•

Oliguria < 500mL/24 hours

•

Thrombocytopenia

•

Elevated hepatic enzymes or impaired liver function

•

Persistent headache, visual disturbances, other cerebral disturbances

•

Persistent epigastric pain or right upper-quadrant pain

• Fetal growth restriction
Eclampsia
•

Presence of preeclampsia

•

Seizures that cannot be attributed to any other causes

Adapted from the National High Blood Pressure Program Working Group Report on
High Blood Pressure in Pregnancy (44).
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Table 2. Maternal Characteristics by Group
Nuchal

Genetic

Chorionic Villus

Translucency

Amniocentesis

Sampling

Mean Maternal Age (years)

32.9 (± 5.1)

36.9 (± 3.8)

36.2 (± 4.8)

Gravidity

2 (range 1-9)

2 (range 1-8)

3 ( range 1-8)

Caucasian

77/100 (77%)

87/105 (82.8 %)

88/107 (82.2%)

African-American

10/100 (10%)

3/105 (2.8%)

3/107 (2.8%)

Asian

4/100 (4%)

9/105 (8.6%)

5/107 (4.7%)

Hispanic

4/100 (4%)

2/105 (1.9%)

5/107 (4.7%)

Other

5/100 (5%)

4/105 (3.8%)

6/107 (5.6%)

11/124 (8.9%)

9/119 (7.6%)

13/207 (6.3%)

Nonsmoker

112/124 (90.3%)

112/117 (95.7%)

200/207 (96.6%)

Current smoker

6/124 (4.8%)

3/117 (2.6%)

3/207 (1.4%)

Ex-smoker

6/124 (4.8%)

2/117 (1.7%)

4/207 (1.9%)

37.7 (± 5.0)

37.8 (± 4.8)

35.0 (± 8.9)

3285.7 (± 747.6)

3264.3 (± 666.5)

3275.2 (± 698.9)

Race

Presence of Diabetes
Smoking Status

Gestational Age at Delivery
(weeks)
Birthweight (grams)
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Table 3. Prevalence of Hypertensive Disorders by Group
Nuchal

Genetic

Translucency

Amniocentesis Sampling

(all groups)

(n = 124)

(n = 119)

(n = 205)

(n = 448)

4 (3.2%)

5 (4.2%)

7 (3.4%)

16 (3.6%)

Current GHTN

4 (3.2%)

1 (0.8%)

2 (1.0%)

7 (1.6%)

History of GHTN

5 (4.0%)

2 (1.7%)

3 (1.5%)

10 (2.2%)

Mild

1 (0.8%)

0 (0.0%)

3 (1.5%)

4 (0.9%)

Severe

3 (2.4%)

3 (2.5%)

2 (1.0%)

8 (1.8%)

Chronic Hypertension

Chorionic Villus

Total

Gestational
Hypertension

Preeclampsia

CVS and Hypertensive Disorders of Pregnancy
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Table 4. Association Between Hypertensive Disorders and CVS
Unadjusted Odds Ratio

Adjusted Odds RatioA

(95% Confidence Interval) (95% Confidence Interval)
Gestational Hypertension
Nuchal Translucency

1.0

1.0

Genetic Amniocentesis

3.5 (0.6 – 19.3)

1.9 (0.2 – 170.1)

Chorionic Villus Sampling

0.9 (0.1 – 9.6)

0.4 (0.03 – 4.7)

1.0

1.0

Genetic Amniocentesis

0.8 (0.2 – 3.5)

1.04 (0.19 – 5.80)

Chorionic Villus Sampling

0.8 (0.2 – 2.8)

0.93 (0.8 – 1.07)

Preeclampsia
Nuchal Translucency

A

Adjusted for age and race

Table 5. Unadjusted Odds Ratio of Hypertensive Disorders and Race
Race

Gestational Hypertension

Preeclampsia

Caucasian

1.0

1.0

African-American 18.8 (95% CI 3.5 – 102.6)A 1.0
Asian

1.0

1.0

Hispanic

1.0

7.8 (95% CI 1.4 – 42.8)A

Other

1.0

1.0

A

p < 0.05
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Table 6. Unadjusted Odds Ratio of Hypertensive Disorders and Smoking
Smoking Status Gestational Hypertension Preeclampsia
Nonsmoker

1.0

1.0

Current smoker 8.2 (95% CI 0.9 – 76.4)

1.0

Ex-smoker

1.0

7.4 (95% CI 0.8 – 68.9)
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